3-148991649-T-C
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_004130.4(GYG1):c.7+2T>C variant causes a splice donor, intron change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_004130.4 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GYG1 | NM_004130.4 | c.7+2T>C | splice_donor_variant, intron_variant | Intron 1 of 7 | ENST00000345003.9 | NP_004121.2 | ||
GYG1 | NM_001184720.2 | c.7+2T>C | splice_donor_variant, intron_variant | Intron 1 of 6 | NP_001171649.1 | |||
GYG1 | NM_001184721.2 | c.7+2T>C | splice_donor_variant, intron_variant | Intron 1 of 5 | NP_001171650.1 | |||
GYG1 | XM_017006275.2 | c.-35+2T>C | splice_donor_variant, intron_variant | Intron 1 of 5 | XP_016861764.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1388136Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 686174
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Glycogen storage disease XV;C4015452:Polyglucosan body myopathy type 2 Pathogenic:1
This variant has not been reported in the literature in individuals affected with GYG1-related conditions. This sequence change affects a donor splice site in intron 1 of the GYG1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GYG1 are known to be pathogenic (PMID: 20357282, 25272951). This variant is not present in population databases (gnomAD no frequency). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -
Polyglucosan body myopathy type 2 Pathogenic:1
Variant summary: GYG1 c.7+2T>C is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant was absent in 135342 control chromosomes. To our knowledge, no occurrence of c.7+2T>C in individuals affected with Polyglucosan Body Myopathy Type 2 and no experimental evidence demonstrating its impact on protein function have been reported. No submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at